222 related articles for article (PubMed ID: 28756642)
1. Factors influencing the quality of Myrmecia pilosula (Jack Jumper) ant venom for use in in vitro and in vivo diagnoses of allergen sensitization and in allergen immunotherapy.
Wanandy T; Dwyer HE; McLean L; Davies NW; Nichols D; Gueven N; Brown SGA; Wiese MD
Clin Exp Allergy; 2017 Nov; 47(11):1478-1490. PubMed ID: 28756642
[TBL] [Abstract][Full Text] [Related]
2. Pharmaceutical and preclinical evaluation of Advax adjuvant as a dose-sparing strategy for ant venom immunotherapy.
Wanandy T; Honda-Okubo Y; Davies NW; Rose HE; Heddle RJ; Brown SGA; Woodman RJ; Petrovsky N; Wiese MD
J Pharm Biomed Anal; 2019 Aug; 172():1-8. PubMed ID: 31009889
[TBL] [Abstract][Full Text] [Related]
3. Towards complete identification of allergens in Jack Jumper (Myrmecia pilosula) ant venom and their clinical relevance: An immunoproteomic approach.
Wanandy T; Wilson R; Gell D; Rose HE; Gueven N; Davies NW; Brown SGA; Wiese MD
Clin Exp Allergy; 2018 Sep; 48(9):1222-1234. PubMed ID: 29975807
[TBL] [Abstract][Full Text] [Related]
4. Myrmecia pilosula (Jack Jumper) ant venom: validation of a procedure to standardise an allergy vaccine.
Wiese MD; Milne RW; Davies NW; Chataway TK; Brown SG; Heddle RJ
J Pharm Biomed Anal; 2008 Jan; 46(1):58-65. PubMed ID: 17933477
[TBL] [Abstract][Full Text] [Related]
5. Stability of Myrmecia pilosula (Jack Jumper) Ant venom for use in immunotherapy.
Wiese MD; Davies NW; Chataway TK; Milne RW; Brown SG; Heddle RJ
J Pharm Biomed Anal; 2011 Jan; 54(2):303-10. PubMed ID: 20869831
[TBL] [Abstract][Full Text] [Related]
6. Identification of an IgE-binding determinant of the major allergen Myr p I from the venom of the Australian jumper ant Myrmecia pilosula.
Donovan GR; Street MD; Baldo BA; Alewood D; Alewood P; Sutherland S
Biochim Biophys Acta; 1994 Jan; 1204(1):48-52. PubMed ID: 7508264
[TBL] [Abstract][Full Text] [Related]
7. Ant allergy in Asia and Australia.
Shek LP; Ngiam NS; Lee BW
Curr Opin Allergy Clin Immunol; 2004 Aug; 4(4):325-8. PubMed ID: 15238800
[TBL] [Abstract][Full Text] [Related]
8. Characterisation of major peptides in 'jack jumper' ant venom by mass spectrometry.
Davies NW; Wiese MD; Brown SG
Toxicon; 2004 Feb; 43(2):173-83. PubMed ID: 15019477
[TBL] [Abstract][Full Text] [Related]
9. Identification of jack-jumper ant (Myrmecia pilosula) venom allergens.
Ford SA; Baldo BA; Weiner J; Sutherland S
Clin Exp Allergy; 1991 Mar; 21(2):167-71. PubMed ID: 2043985
[TBL] [Abstract][Full Text] [Related]
10. Myrmecia pilosula (Jack Jumper) ant venom: identification of allergens and revised nomenclature.
Wiese MD; Brown SG; Chataway TK; Davies NW; Milne RW; Aulfrey SJ; Heddle RJ
Allergy; 2007 Apr; 62(4):437-43. PubMed ID: 17362256
[TBL] [Abstract][Full Text] [Related]
11. Proteomic analysis of Myrmecia pilosula (jack jumper) ant venom.
Wiese MD; Chataway TK; Davies NW; Milne RW; Brown SG; Gai WP; Heddle RJ
Toxicon; 2006 Feb; 47(2):208-17. PubMed ID: 16376960
[TBL] [Abstract][Full Text] [Related]
12. Expression of jumper ant (Myrmecia pilosula) venom allergens: post-translational processing of allergen gene products.
Donovan GR; Street MD; Tetaz T; Smith AI; Alewood D; Alewood P; Sutherland SK; Baldo BA
Biochem Mol Biol Int; 1996 Aug; 39(5):877-85. PubMed ID: 8866004
[TBL] [Abstract][Full Text] [Related]
13. Pilosulins: a review of the structure and mode of action of venom peptides from an Australian ant Myrmecia pilosula.
Wanandy T; Gueven N; Davies NW; Brown SG; Wiese MD
Toxicon; 2015 May; 98():54-61. PubMed ID: 25725257
[TBL] [Abstract][Full Text] [Related]
14. Prevalence, severity, and natural history of jack jumper ant venom allergy in Tasmania.
Brown SG; Franks RW; Baldo BA; Heddle RJ
J Allergy Clin Immunol; 2003 Jan; 111(1):187-92. PubMed ID: 12532117
[TBL] [Abstract][Full Text] [Related]
15. Using time-resolved fluorescence to measure serum venom-specific IgE and IgG.
van Eeden PE; Wiese MD; Aulfrey S; Hales BJ; Stone SF; Brown SG
PLoS One; 2011 Jan; 6(1):e16741. PubMed ID: 21304970
[TBL] [Abstract][Full Text] [Related]
16. Molecular cloning and characterization of the major allergen Myr p II from the venom of the jumper ant Myrmecia pilosula: Myr p I and Myr p II share a common protein leader sequence.
Street MD; Donovan GR; Baldo BA
Biochim Biophys Acta; 1996 Feb; 1305(1-2):87-97. PubMed ID: 8605256
[TBL] [Abstract][Full Text] [Related]
17. Molecular cloning and characterization of a major allergen (Myr p I) from the venom of the Australian jumper ant, Myrmecia pilosula.
Donovan GR; Baldo BA; Sutherland S
Biochim Biophys Acta; 1993 Jan; 1171(3):272-80. PubMed ID: 7678752
[TBL] [Abstract][Full Text] [Related]
18. Component-resolved evaluation of the content of major allergens in therapeutic extracts for specific immunotherapy of honeybee venom allergy.
Blank S; Etzold S; Darsow U; Schiener M; Eberlein B; Russkamp D; Wolf S; Graessel A; Biedermann T; Ollert M; Schmidt-Weber CB
Hum Vaccin Immunother; 2017 Oct; 13(10):2482-2489. PubMed ID: 28494206
[TBL] [Abstract][Full Text] [Related]
19. Immediate allergic reactions to Myrmecia ant stings: immunochemical analysis of Myrmecia venoms.
Street MD; Donovan GR; Baldo BA; Sutherland S
Clin Exp Allergy; 1994 Jun; 24(6):590-7. PubMed ID: 7922779
[TBL] [Abstract][Full Text] [Related]
20. The development of Jack Jumper ant venom immunotherapy: our 25 years' experience.
Wanandy T; Le TA; Lau WY; Wiese MD; Heddle RJ; Brown SGA
Intern Med J; 2023 Sep; 53(9):1716-1721. PubMed ID: 37743244
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
